AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11830607
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus etoposide or paclitaxel (exact dosage and duration not specified)
Trial: 10362172
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 2.5 mg
Trial: 10362172
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 5 mg
Trial: 10362172
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 10 mg
Trial: 7543393
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (bisphosphonates, radioisotopes, local treatments)
Trial: 20481050
Drug: Structural resonance
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural resonance electromagnetic therapy (SREMT) - 10-12 daily sessions of 43 minutes each on a Rematerp apparatus.
Trial: 20481050
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving the same medical and physiotherapeutic treatment without SREMT.
Trial: 15105203
Drug: i.v. midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. midazolam (0.09 mg/kg)
Trial: 9625132
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil extract (EPA 3.2 g, DHA 2.4 g)
Trial: 30954341
Drug: High-nitrate salad
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-nitrate salad (twice daily for 10 days)
Trial: 26721132
Drug: Medication (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (3 mg eszopiclone tablets orally before sleep, once every night for 6 weeks)
Trial: 23882870
Drug: Light cigarette
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light cigarette (0.6 mg of nicotine, 8 mg of tar, and 9 mg of carbon monoxide)
Trial: 23882870
Drug: Regular cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular cigarette (0.9 mg of nicotine, 12 mg of tar, and 12 mg of carbon monoxide)
Trial: 21729284
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg) administered orally at 21:00 h for five consecutive days
Trial: 9221864
Drug: Topical nitroglycerine
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerine (0.2 percent glyceryl trinitrate ointment)
Trial: 9221864
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic gel (lignocaine)
Trial: 8213579
Drug: rt-PA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (10 mg bolus, followed by 50 mg in the first hour, and 20 mg/hour for the next 2 hours)
Trial: 26898862
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid injection combined with acid-suppressive therapy (experimental group)
Trial: 26898862
Drug: Acid-suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-suppressive therapy only (control group)
Trial: 24529580
Drug: Silodosin 8-mg
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8-mg once-daily (QD)
Trial: 24529580
Drug: Silodosin 4-mg
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 4-mg twice-daily (BID)
Trial: 17499988
Drug: Laboratory and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laboratory and hormone replacement studies
Trial: 15072701
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) doses of 450 microg and 400 microg
Trial: 10188768
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-10 (10 ng/mL)
Trial: 7493146
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (60 mg/kg, i.v.)
Trial: 30995433
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine + Exenatide (Iglar + GLP-1)
Trial: 30995433
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (Iglar)
Trial: 28026920
Drug: Naltrexone sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone sustained release (SR) 32 mg / Bupropion SR 360 mg + Comprehensive Lifestyle Intervention (CLI)
Trial: 25827441
Drug: Empagliflozin 12.5
RxNorm normalized name: empagliflozin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 12.5 mg twice daily
Trial: 25827441
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 mg twice daily
Trial: 1696670
Drug: Nicardipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (4 doses: 1.25, 2.5, 5.0, and 10.0 mg administered by i.v. infusion over 40 min)
Trial: 1245165
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg digoxin with 1100 mg magnesium-aluminium-silicate-hydrate (n=4)
Trial: 1245165
Drug: 0.375 mg
RxNorm normalized name: vitamin A 0.375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375 mg digoxin with 1100 mg magnesium-aluminium-silicate-hydrate (n=4)
Trial: 1245165
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg digoxin with 1000 mg dimagnesium-aluminium-trisilicate (n=5)
Trial: 1245165
Drug: 0.375 mg
RxNorm normalized name: vitamin A 0.375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375 mg digoxin with 1000 mg dimagnesium-aluminium-trisilicate (n=5)
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during an 8-week open-label, randomized, escalating dose Pharmacokinetic Phase
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during a 16-week Long-Term Effectiveness Phase
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during a 28-week double-blind Discontinuation Phase
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during an 8-week open-label Restabilization Phase
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during an 8-week double-blind, parallel-group, placebo-controlled Efficacy Phase
Trial: 18700004
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment during an open-label Long-Term Effectiveness lasting either 16 or 24 weeks
Trial: 15548718
Drug: Intradermal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal administration of granulocyte macrophage-colony stimulating factor around the excision site of stage I primary melanoma tumors
Trial: 25062651
Drug: Weight-based insulin
RxNorm normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight-based insulin glargine dose titration regimen
Trial: 25062651
Drug: Glucose level-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose level-based insulin glargine dose titration regimen
Trial: 25062651
Drug: Current dose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current dose-based insulin glargine dose titration regimen
Trial: 21980058
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 μg)
Trial: 21980058
Drug: Salmeterol/Fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/Fluticasone propionate (50/250 μg)
Trial: 21980058
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (250 μg)
Trial: 17877164
Drug: A +
RxNorm normalized name: Vital E- A + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A + C vaccine
Trial: 2645508
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Tetrazepam, Baclofen, Tizanidine)
Trial: 30352770
Drug: Biomechanical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomechanical therapy with a foot-worn biomechanical device
Trial: 29071986
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy combined with nutrition consultation
Trial: 25892145
Drug: Methotrexate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (40 mg/m2 per week)
Trial: 24165884
Drug: Etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 200 mg bid for 14 days with cocktail on days 1 and 14
Trial: 24165884
Drug: Etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 200 mg bid for 12 days with digoxin on day 8
Trial: 22852050
Drug: Carbohydrate-only (CHO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-only (CHO; 75 g per beverage)
Trial: 22852050
Drug: High-carbohydrate/low-protein (HCLP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate/low-protein (HCLP; 45 g CHO, 25 g Pro, 0.5 g fat)
Trial: 22852050
Drug: Low-carbohydrate/high-protein (LCHP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate/high-protein (LCHP; 8 g CHO, 55 g Pro, 4 g fat)
Trial: 22852050
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (CHO, HCLP, LCHP)
Trial: 17519069
Drug: LOP/SIM 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOP/SIM 2 mg/125 mg
Trial: 17519069
Drug: LOP 2
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4 g in 100 mL TOPICAL OIL [WONG LOP KONG MEDICATED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOP 2 mg
Trial: 17519069
Drug: SIM 125
RxNorm normalized name: Bicarsim 125 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIM 125 mg
Trial: 14688160
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (400 microg 3 h prior to SE)
Trial: 14688160
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 microg 3 h prior to SE)
Trial: 9260007
Drug: Tramadol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (10 mg PCA bolus)
Trial: 9260007
Drug: Tramadol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol + Droperidol (10 mg tramadol + 0.1 mg droperidol PCA bolus)
Trial: 3440104
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal 5 g orally at hourly intervals for 7 h
Trial: 23354809
Drug: Piperacillin/tazobactam dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam dosing strategy of 44.44/5.56 mg/kg/dose every 8 or 12 hours
Trial: 18353242
Drug: HBIG injection
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG injection every four weeks until labor (experimental group with HBsAg positive)
Trial: 18353242
Drug: HBIG injection
RxNorm normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG injection every four weeks until labor (experimental group with both HBsAg and HBeAg positive)
Trial: 12890165
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) 120 mg/day for 14 days
Trial: 12890165
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) 240 mg/day for 14 days
Trial: 12890165
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) 480 mg/day for 14 days
Trial: 10976194
Drug: Lansoprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I)
Trial: 10976194
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II)
Trial: 2878490
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with two injections a day (CTh)
Trial: 30036854
Drug: Injectable disease-modifying
RxNorm normalized name: modified fluid gelatins Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable disease-modifying therapies (iDMTs)
Trial: 22297398
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous zoledronic acid (ZOL)
Trial: 11481623
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 6 MU daily of interferon alfa 2b plus 800 mg of ribavirin
Trial: 11481623
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 6 MU daily of IFN‐alpha2b
Trial: 11481623
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with twice‐daily intravenous administration with 3MU of IFN‐beta
Trial: 11481623
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with daily intravenous administration with 6 MU of IFN‐beta
Trial: 8001404
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide with oxygen inhalation
Trial: 8132369
Drug: Daily antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antibiotic prophylaxis with Phenoxymethylpenicillin (or erythromycin for penicillin-allergic patients)
Trial: 25851632
Drug: EVE/BEV (everolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVE/BEV (everolimus 10 mg/day + bevacizumab 10 mg/kg every 2 weeks)
Trial: 25851632
Drug: IFN/BEV (interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN/BEV (interferon 9 MIU 3 times/week + bevacizumab 10 mg/kg every 2 weeks)
Trial: 23646475
Drug: Xuebijing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing Injection (XI), intravenously injected with 100 mL QI in 100 mL normal saline, twice daily for seven days
Trial: 21494043
Drug: Real-time group
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time group with real-time viewer and polyethylene glycol (500 ml) or metoclopramide (10 mg) if capsule in stomach.
Trial: 21494043
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group without preparation.
Trial: 19138700
Drug: Rod reaction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rod reaction times plotted against the spatial luminance ratio (L(max)/L(min)) between the stimulus and its background.
Trial: 17966177
Drug: Ketoconazole cream
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole cream (n=210)
Trial: 17966177
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream (n=105)
Trial: 11473852
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia plus a titrated IV propofol infusion (LA/PI)
Trial: 28523945
Drug: Menopause-related hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopause-related hormone therapy (MHT)
Trial: 24311403
Drug: Corticosteroid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid administration
Trial: 21205623
Drug: Cisatracurium 20
RxNorm normalized name: cisatracurium 200 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 20 µg kg(‐1), followed by four incremental 10 µg kg(‐1) doses, and the remainder of 100 µg kg(‐1)
Trial: 18206256
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of treatments
Trial: 18206256
Drug: Database of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Database of treatment parameters
Trial: 11513308
Drug: slow-release caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release caffeine (300 mg)
Trial: 11513308
Drug: melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin (5 mg)
Trial: 9756109
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) monotherapy
Trial: 3180201
Drug: Flunarizine 20
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 20 mg by slow intravenous injection
Trial: 27967328
Drug: Pharmacogenomic (PG)
RxNorm normalized name: PG
DrugBank: 1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) (DB11331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic (PG) dosing algorithm
Trial: 25845302
Drug: Non-absorbable 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-absorbable 15 × 10 cm anatomical mesh fixed with 2 ml fibrin sealant (Group 4)
Trial: 20977679
Drug: FTC/TDF (200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF (200/300 mg) + BILR 355/r (150/100 mg)
Trial: 20977679
Drug: BILR 355/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILR 355/r (150/100 mg)
Trial: 19875408
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (Ferinject) 200 mg iron i.v. weekly until iron repletion, then monthly until Week 24
Trial: 14756638
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of excimer laser treatment and topical tacrolimus 0.1% ointment
Trial: 3535811
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg at night
Trial: 3535811
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg at night and Naproxen 500 mg twice daily
Trial: 28993180
Drug: Single-tablet regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet regimen of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg taken once per day for 48 weeks
Trial: 28993180
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate
Trial: 28993180
Drug: Single-tablet regimen
RxNorm normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Trial: 26625418
Drug: Perturbations delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perturbations delivered along the Medio‐Lateral (ML) direction
Trial: 25406652
Drug: CBCT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBCT group - mini-implants placed using CBCT data
Trial: 25406652
Drug: RVG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVG group - mini-implants placed using two-dimensional digital radiographs and a custom made guide
Trial: 15676050
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 100 microg